The first Covid-19 vaccine to be produced in the Arab region will be called Hayat-Vax – and the assembly line is already rolling out two million doses per month.
The joint venture between the UAE, the Chinese firm Sinopharm and the Abu Dhabi-based technology company G42 launched this week, producing the vaccine with its partner Julphar.
The KIZAD-based plant will have three filling lines and five automated packaging lines and once it reaches production capacity, it will turn out 200 million doses a year of Hayat-Vax.
Hayat means ‘life’ in Arabic.
The new research and development hub for life sciences, biotechnology and vaccine production at KIZAD (Khalifa Industrial Zone) is the first-of-its-kind in the Arab world. The launch comes after G42 and Sinopharm’s collaboration on the world’s first phase III clinical trial of inactivated vaccines across the Arab region.
Dubbed 4Humanity, the trials involved more than 43,000 volunteers representing 125 nationalities.
“The UAE, with the guidance of its wise leadership, believes in the importance of strengthening collective international action,” said Sheikh Abdullah bin Zayed Al Nahyan at the launch.
Hayat-Vax is the same inactivated Covid-19 vaccine produced by Sinopharm that the UAE Ministry of Health and Prevention registered last December. Interim results submitted in China show 79.34 percent efficacy.
In March, the UAE national vaccination program achieved the vaccination of more than 52 percent of the country’s population, a process that is being conducted across 205 medical centers.